$CADL
Candel Therapeutics, Inc.

2022 Q1 Form 10-Q Financial Statement

#000095017022009479 Filed on May 12, 2022

View on sec.gov

Income Statement

Concept 2022 Q1 2021 Q1
Revenue $31.00K $31.00K
YoY Change 0.0% 0.0%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $3.600M $1.935M
YoY Change 86.05% 165.8%
% of Gross Profit
Research & Development $5.417M $2.753M
YoY Change 96.77% 69.83%
% of Gross Profit
Depreciation & Amortization $165.0K $26.00K
YoY Change 534.62% -18.75%
% of Gross Profit
Operating Expenses $9.017M $4.688M
YoY Change 92.34% 99.57%
Operating Profit -$8.986M -$4.657M
YoY Change 92.96%
Interest Expense -$175.0K -$12.00K
YoY Change 1358.33% -83.33%
% of Operating Profit
Other Income/Expense, Net $8.112M $179.0K
YoY Change 4431.84% -71.04%
Pretax Income -$874.0K -$4.478M
YoY Change -80.48% 152.71%
Income Tax $0.00
% Of Pretax Income
Net Earnings -$874.0K -$4.478M
YoY Change -80.48% 152.71%
Net Earnings / Revenue -2819.35% -14445.16%
Basic Earnings Per Share -$0.03
Diluted Earnings Per Share -$30.46K -$161.1K
COMMON SHARES
Basic Shares Outstanding 28.69M
Diluted Shares Outstanding 28.69M

Balance Sheet

Concept 2022 Q1 2021 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $94.32M $29.15M
YoY Change 223.55%
Cash & Equivalents $94.32M $29.58M
Short-Term Investments
Other Short-Term Assets $1.325M $319.0K
YoY Change 315.36%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $95.65M $29.47M
YoY Change 224.54%
LONG-TERM ASSETS
Property, Plant & Equipment $4.264M $4.263M
YoY Change 0.02%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $437.0K $1.360M
YoY Change -67.87%
Total Long-Term Assets $5.916M $5.623M
YoY Change 5.21%
TOTAL ASSETS
Total Short-Term Assets $95.65M $29.47M
Total Long-Term Assets $5.916M $5.623M
Total Assets $101.6M $35.09M
YoY Change 189.4%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $1.386M $1.513M
YoY Change -8.39%
Accrued Expenses $3.563M $3.298M
YoY Change 8.04%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $464.0K
YoY Change -100.0%
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $5.472M $5.498M
YoY Change -0.47%
LONG-TERM LIABILITIES
Long-Term Debt $20.53M $502.0K
YoY Change 3988.65%
Other Long-Term Liabilities $11.80M $7.531M
YoY Change 56.73%
Total Long-Term Liabilities $32.33M $8.033M
YoY Change 302.44%
TOTAL LIABILITIES
Total Short-Term Liabilities $5.472M $5.498M
Total Long-Term Liabilities $32.33M $8.033M
Total Liabilities $37.80M $13.53M
YoY Change 179.36%
SHAREHOLDERS EQUITY
Retained Earnings -$81.17M
YoY Change
Common Stock $144.9M
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $63.76M -$27.50M
YoY Change
Total Liabilities & Shareholders Equity $101.6M $35.09M
YoY Change 189.4%

Cashflow Statement

Concept 2022 Q1 2021 Q1
OPERATING ACTIVITIES
Net Income -$874.0K -$4.478M
YoY Change -80.48% 152.71%
Depreciation, Depletion And Amortization $165.0K $26.00K
YoY Change 534.62% -18.75%
Cash From Operating Activities -$8.053M -$5.627M
YoY Change 43.11% 154.16%
INVESTING ACTIVITIES
Capital Expenditures $171.0K $229.0K
YoY Change -25.33%
Acquisitions
YoY Change
Other Investing Activities $0.00
YoY Change -100.0%
Cash From Investing Activities -$171.0K -$229.0K
YoY Change -25.33% -101.19%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 19.92M 112.0K
YoY Change 17682.14% 11100.0%
NET CHANGE
Cash From Operating Activities -8.053M -5.627M
Cash From Investing Activities -171.0K -229.0K
Cash From Financing Activities 19.92M 112.0K
Net Change In Cash 11.69M -5.744M
YoY Change -303.55% -133.65%
FREE CASH FLOW
Cash From Operating Activities -$8.053M -$5.627M
Capital Expenditures $171.0K $229.0K
Free Cash Flow -$8.224M -$5.856M
YoY Change 40.44% 164.5%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2022Q1 us-gaap Preferred Stock Value
PreferredStockValue
CY2022Q1 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2022Q1 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q1
CY2022Q1 us-gaap Number Of Operating Segments
NumberOfOperatingSegments
1
CY2021Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2021Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2022Q1 dei Amendment Flag
AmendmentFlag
false
CY2022Q1 dei Entity Central Index Key
EntityCentralIndexKey
0001841387
CY2022Q1 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2022Q1 dei Document Type
DocumentType
10-Q
CY2022Q1 dei Document Quarterly Report
DocumentQuarterlyReport
true
CY2022Q1 dei Document Period End Date
DocumentPeriodEndDate
2022-03-31
CY2022Q1 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2022
CY2022Q1 dei Document Transition Report
DocumentTransitionReport
false
CY2022Q1 dei Entity File Number
EntityFileNumber
001-40629
CY2022Q1 dei Entity Registrant Name
EntityRegistrantName
CANDEL THERAPEUTICS, INC.
CY2022Q1 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
CY2022Q1 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
52-2214851
CY2022Q1 dei Entity Address Address Line1
EntityAddressAddressLine1
117 Kendrick St
CY2022Q1 dei Entity Address Address Line2
EntityAddressAddressLine2
Suite 450
CY2022Q1 dei Entity Address City Or Town
EntityAddressCityOrTown
Needham
CY2022Q1 dei Entity Address State Or Province
EntityAddressStateOrProvince
MA
CY2022Q1 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
02494
CY2022Q1 dei City Area Code
CityAreaCode
617
CY2022Q1 dei Local Phone Number
LocalPhoneNumber
916-5445
CY2022Q1 dei Security12b Title
Security12bTitle
Common Stock, par value $0.01 per share
CY2022Q1 dei Trading Symbol
TradingSymbol
CADL
CY2022Q1 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
1325000
CY2021Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
1590000
CY2022Q1 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
3563000
CY2021Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
3438000
CY2022Q1 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
429000
CY2022Q1 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
94000
CY2021Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
334000
CY2022Q1 dei Security Exchange Name
SecurityExchangeName
NASDAQ
CY2022Q1 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2022Q1 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2022Q1 dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
CY2022Q1 dei Entity Small Business
EntitySmallBusiness
true
CY2022Q1 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
CY2022Q1 dei Entity Ex Transition Period
EntityExTransitionPeriod
false
CY2022Q1 dei Entity Shell Company
EntityShellCompany
false
CY2022Q1 dei Entity Bankruptcy Proceedings Reporting Current
EntityBankruptcyProceedingsReportingCurrent
true
CY2022Q2 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
28693151
CY2022Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
94321000
CY2021Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
82642000
CY2021Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
2303000
CY2022Q1 us-gaap Assets Current
AssetsCurrent
95646000
CY2021Q4 us-gaap Assets Current
AssetsCurrent
84945000
CY2022Q1 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
4264000
CY2021Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
3836000
CY2022Q1 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
1215000
CY2022Q1 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
437000
CY2021Q4 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
424000
CY2022Q1 us-gaap Assets
Assets
101562000
CY2021Q4 us-gaap Assets
Assets
89205000
CY2022Q1 us-gaap Accounts Payable Current
AccountsPayableCurrent
1386000
CY2022Q1 us-gaap Liabilities Current
LiabilitiesCurrent
5472000
CY2021Q4 us-gaap Liabilities Current
LiabilitiesCurrent
5362000
CY2021Q4 us-gaap Deferred Rent Credit Noncurrent
DeferredRentCreditNoncurrent
894000
CY2022Q1 us-gaap Long Term Loans From Bank
LongTermLoansFromBank
19943000
CY2022Q1 us-gaap Other Long Term Debt Noncurrent
OtherLongTermDebtNoncurrent
582000
CY2021Q4 us-gaap Other Long Term Debt Noncurrent
OtherLongTermDebtNoncurrent
560000
CY2022Q1 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
1838000
CY2022Q1 cadl Warrant Liability Noncurrent
WarrantLiabilityNoncurrent
9965000
CY2021Q4 cadl Warrant Liability Noncurrent
WarrantLiabilityNoncurrent
18252000
CY2022Q1 us-gaap Liabilities
Liabilities
37800000
CY2021Q4 us-gaap Liabilities
Liabilities
25068000
CY2022Q1 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.01
CY2021Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.01
CY2022Q1 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2021Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2022Q1 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2021Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1935000
CY2022Q1 us-gaap Operating Expenses
OperatingExpenses
9017000
CY2021Q1 us-gaap Operating Expenses
OperatingExpenses
4688000
CY2022Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-8986000
CY2021Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-4657000
CY2022Q1 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2021Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2021Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2022Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
CY2021Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
CY2022Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
150000000
CY2021Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
150000000
CY2022Q1 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
28693151
CY2022Q1 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
28693151
CY2021Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
28689842
CY2021Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
28689842
CY2022Q1 us-gaap Common Stock Value
CommonStockValue
287000
CY2021Q4 us-gaap Common Stock Value
CommonStockValue
286000
CY2022Q1 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
144644000
CY2021Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
144146000
CY2022Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-81169000
CY2021Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-80295000
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
63762000
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
64137000
CY2022Q1 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
101562000
CY2021Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
89205000
CY2022Q1 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
31000
CY2021Q1 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
31000
CY2022Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
5417000
CY2021Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
2753000
CY2022Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
3600000
CY2021Q1 us-gaap Nonoperating Gains Losses
NonoperatingGainsLosses
191000
CY2022Q1 us-gaap Investment Income Net
InvestmentIncomeNet
-175000
CY2021Q1 us-gaap Investment Income Net
InvestmentIncomeNet
-12000
CY2022Q1 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-8287000
CY2022Q1 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
8112000
CY2021Q1 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
179000
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-874000
CY2021Q1 us-gaap Net Income Loss
NetIncomeLoss
-4478000
CY2022Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.03
CY2021Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.38
CY2022Q1 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
28690511
CY2021Q1 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
11647789
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
64137000
CY2022Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
6000
CY2022Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
828000
CY2022Q1 us-gaap Adjustments To Additional Paid In Capital Mark To Market
AdjustmentsToAdditionalPaidInCapitalMarkToMarket
-335000
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-874000
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
63762000
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
-23562000
CY2021Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
35000
CY2021Q1 cadl Stock Issued During Period Value Warrant Exercised
StockIssuedDuringPeriodValueWarrantExercised
77000
CY2021Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
431000
CY2021Q1 us-gaap Net Income Loss
NetIncomeLoss
-4478000
CY2021Q1 us-gaap Stockholders Equity
StockholdersEquity
-27497000
CY2022Q1 us-gaap Profit Loss
ProfitLoss
-874000
CY2021Q1 us-gaap Profit Loss
ProfitLoss
-4478000
CY2022Q1 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
165000
CY2021Q1 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
26000
CY2022Q1 us-gaap Share Based Compensation
ShareBasedCompensation
492000
CY2021Q1 us-gaap Share Based Compensation
ShareBasedCompensation
431000
CY2022Q1 cadl Non Cash Lease Expense
NonCashLeaseExpense
50000
CY2022Q1 cadl Non Cash Interest Expense
NonCashInterestExpense
22000
CY2021Q1 cadl Non Cash Interest Expense
NonCashInterestExpense
20000
CY2022Q1 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-8287000
CY2022Q1 cadl Accretion Of Debt Discount
AccretionOfDebtDiscount
32000
CY2022Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-979000
CY2021Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
225000
CY2022Q1 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-579000
CY2021Q1 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
173000
CY2022Q1 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
90000
CY2021Q1 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-1275000
CY2022Q1 us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
-31000
CY2021Q1 us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
-31000
CY2021Q1 cadl Increase Decrease In Deferred Rent
IncreaseDecreaseInDeferredRent
9000
CY2022Q1 us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-112000
CY2021Q1 us-gaap Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
277000
CY2022Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-8053000
CY2021Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-5627000
CY2022Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
171000
CY2021Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
229000
CY2022Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-171000
CY2021Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-229000
CY2022Q1 us-gaap Proceeds From Bank Debt
ProceedsFromBankDebt
19910000
CY2021Q1 us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
77000
CY2022Q1 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
6000
CY2021Q1 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
35000
CY2022Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
19916000
CY2021Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
112000
CY2022Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
11692000
CY2021Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-5744000
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
83066000
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
35319000
CY2022Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
94758000
CY2021Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
29575000
CY2022Q1 us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
85000
CY2021Q1 us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
6000
CY2022Q1 us-gaap Interest Paid Net
InterestPaidNet
117000
CY2021Q4 us-gaap Restricted Cash
RestrictedCash
424000
CY2021Q4 us-gaap Operating Leases Future Minimum Payments Due In Four Years
OperatingLeasesFutureMinimumPaymentsDueInFourYears
613000
CY2021Q4 us-gaap Operating Leases Future Minimum Payments Due In Five Years
OperatingLeasesFutureMinimumPaymentsDueInFiveYears
415000
CY2021Q4 us-gaap Operating Leases Future Minimum Payments Due
OperatingLeasesFutureMinimumPaymentsDue
2776000
CY2022Q1 us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
2368000
CY2022Q1 us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
421000
CY2021Q1 us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
1850000
CY2022Q1 cadl Number Of Product Candidates
NumberOfProductCandidates
2
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-874000
CY2021Q1 us-gaap Net Income Loss
NetIncomeLoss
-4478000
CY2022Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-81169000
CY2022Q1 cadl Cash And Cash Equivalent Maturity Period
CashAndCashEquivalentMaturityPeriod
P90D
CY2022Q1 us-gaap Restricted Cash
RestrictedCash
437000
CY2022Q1 cadl Expected Dividend Assumed
ExpectedDividendAssumed
0
CY2022Q1 us-gaap Use Of Estimates
UseOfEstimates
<p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;min-width:fit-content;">Use of estimates</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:3.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">The </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.5pt;font-family:Arial;min-width:fit-content;">preparation of the Company’s </span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.5pt;font-family:Arial;min-width:fit-content;">condensed </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.5pt;font-family:Arial;min-width:fit-content;">consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, and related disclosure of contingent assets and liabilities at the date of the financial statements and reported amounts of revenue and expenses during the reporting period. On an ongoing basis, the Company’s management evaluates its estimates, which include but are not limited to management’s judgments of accrued expenses, valuation of stock-based option awards, valuations of warrants, and income taxes. Actual results could differ from those estimates.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.5pt;font-family:Arial;min-width:fit-content;"> </span></p><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.5pt;font-family:Arial;min-width:fit-content;">Prior to the IPO, the Company utilized significant estimates and assumptions in determining the fair value of its common stock. The Company has utilized various valuation methodologies in accordance with the framework of the American Institute of Certified Public Accountants Technical Practice Aid, Valuation of Privately-Held Company Equity Securities Issued as Compensation (the "Practice Aid"), to estimate the fair value of its common stock and warrants. Each valuation methodology includes estimates and assumptions that require the Company’s judgment. These estimates and assumptions include a number of objective and subjective factors, including external market conditions, the prices at which the Company sold shares of preferred stock, the superior rights and preferences of securities senior to the Company’s common stock at the time of, and the likelihood of, achieving a liquidity event, such as an initial public offering or sale. Significant changes to the key assumptions used in the valuations could result in different fair values of common stock at each valuation</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;"> date. </span>
CY2022Q1 us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;min-width:fit-content;">Concentrations of credit risk</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:4.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.5pt;font-family:Arial;min-width:fit-content;">Financial instruments that potentially expose the Company to concentrations of credit risk consist primarily of cash and cash equivalents and marketable securities. Periodically, the Company maintains deposits and investments in accredited financial institutions in-excess of the federally insured limits. The Company deposits its cash in financial institutions with a high credit quality and has not experienced any losses on such accounts and does not believe it is exposed to any unusual credit risk beyond the normal risk associated with commercial banking relationships.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.5pt;font-family:Arial;min-width:fit-content;"> </span></p>
CY2021Q4 us-gaap Impairment Of Long Lived Assets Held For Use
ImpairmentOfLongLivedAssetsHeldForUse
553000
CY2022Q1 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2022Q1 cadl Percentage Income Taxes Benefits Upon Ultimate Settlement
PercentageIncomeTaxesBenefitsUponUltimateSettlement
0.50
CY2022Q1 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
4781000
CY2021Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
4188000
CY2022Q1 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
517000
CY2021Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
352000
CY2022Q1 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
4264000
CY2021Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
3836000
CY2022Q1 us-gaap Depreciation And Amortization
DepreciationAndAmortization
165000
CY2021Q1 us-gaap Depreciation And Amortization
DepreciationAndAmortization
26000
CY2022Q1 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
2224000
CY2021Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
2096000
CY2022Q1 cadl Accrued Third Party Research And Development Expenses Current
AccruedThirdPartyResearchAndDevelopmentExpensesCurrent
718000
CY2021Q4 cadl Accrued Third Party Research And Development Expenses Current
AccruedThirdPartyResearchAndDevelopmentExpensesCurrent
632000
CY2022Q1 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
621000
CY2021Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
710000
CY2022Q1 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
3563000
CY2021Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
3438000
CY2022Q1 us-gaap Debt Instrument Carrying Amount
DebtInstrumentCarryingAmount
20000000
CY2022Q1 cadl Debt Instrument Final Payment Fee
DebtInstrumentFinalPaymentFee
900000
CY2022Q1 us-gaap Debt Instrument Unamortized Discount
DebtInstrumentUnamortizedDiscount
989000
CY2022Q1 cadl Debt Instrument Accretion Of Debt Discount
DebtInstrumentAccretionOfDebtDiscount
32000
CY2022Q1 us-gaap Long Term Loans From Bank
LongTermLoansFromBank
19943000
CY2022Q1 us-gaap Operating Lease Cost
OperatingLeaseCost
90000
CY2022Q1 us-gaap Variable Lease Cost
VariableLeaseCost
47000
CY2022Q1 us-gaap Lease Cost
LeaseCost
137000
CY2022Q1 us-gaap Operating Lease Payments
OperatingLeasePayments
141000
CY2022Q1 us-gaap Operating Lease Payments
OperatingLeasePayments
141000
CY2022Q1 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P4Y4M24D
CY2022Q1 cadl Weighted Average Incremental Borrowing Rate
WeightedAverageIncrementalBorrowingRate
0.0702
CY2022Q1 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
427000
CY2022Q1 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
582000
CY2022Q1 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
598000
CY2022Q1 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
613000
CY2022Q1 us-gaap Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
415000
CY2022Q1 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
2635000
CY2022Q1 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
368000
CY2022Q1 us-gaap Operating Lease Liability
OperatingLeaseLiability
2267000
CY2021Q1 us-gaap Lease And Rental Expense
LeaseAndRentalExpense
171000
CY2021Q4 us-gaap Operating Leases Future Minimum Payments Due Current
OperatingLeasesFutureMinimumPaymentsDueCurrent
567000
CY2021Q4 us-gaap Operating Leases Future Minimum Payments Due In Two Years
OperatingLeasesFutureMinimumPaymentsDueInTwoYears
583000
CY2021Q4 us-gaap Operating Leases Future Minimum Payments Due In Three Years
OperatingLeasesFutureMinimumPaymentsDueInThreeYears
598000
CY2021Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2022Q1 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.01
CY2021Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.01
CY2022Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
150000000
CY2021Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
150000000
CY2022Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
CY2021Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
CY2022Q1 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
28693151
CY2022Q1 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
28693151
CY2021Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
28689842
CY2021Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
28689842
CY2022Q1 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
15314323
CY2021Q4 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
14170038
CY2021Q3 us-gaap Stockholders Equity Reverse Stock Split
StockholdersEquityReverseStockSplit
one-for-2.4579
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
1981114
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
4783333
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
2.34
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
1044400
CY2022Q1 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
4.13
CY2022Q1 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
3309
CY2022Q1 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
1.55
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
5824424
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
2.67
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
2465478
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
1.92
CY2022Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Number Of Shares
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares
3358946
CY2022Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Options Forfeited Weighted Average Grant Date Fair Value
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue
3.22
CY2021Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P6Y3M
CY2021Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0106
CY2021Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.8833
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
CY2021Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
CY2021Q1 cadl Share Based Compensation Arrangement By Share Based Payment Award Waited Average Assumptions Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardWaitedAverageAssumptionsExercisePrice
4.97
CY2021Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
4970
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue
1177000
CY2021Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue
210000
CY2022Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
492000
CY2021Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
431000
CY2022Q1 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Share Based Awards Other Than Options
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions
7543000
CY2021Q1 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Share Based Awards Other Than Options
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions
5423000
CY2022Q1 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P2Y5M12D
CY2021Q1 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P2Y7M2D
CY2022Q1 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
31000
CY2021Q1 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
31000
CY2021Q1 us-gaap Net Income Loss
NetIncomeLoss
-4478000
CY2022Q1 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
28690511
CY2022Q1 cadl Noncancelable Operating Lease Expiration Date
NoncancelableOperatingLeaseExpirationDate
2026
CY2022Q1 us-gaap Loss Contingency Loss In Period
LossContingencyLossInPeriod
0
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-874000
CY2021Q1 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
11647789
CY2022Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.03
CY2021Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.38
CY2022Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
13332132
CY2021Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
18690671

Files In Submission

Name View Source Status
0000950170-22-009479-index-headers.html Edgar Link pending
0000950170-22-009479-index.html Edgar Link pending
0000950170-22-009479.txt Edgar Link pending
0000950170-22-009479-xbrl.zip Edgar Link pending
cadl-20220331.htm Edgar Link pending
cadl-20220331.xsd Edgar Link pending
cadl-20220331_cal.xml Edgar Link unprocessable
cadl-20220331_def.xml Edgar Link unprocessable
cadl-20220331_htm.xml Edgar Link completed
cadl-20220331_lab.xml Edgar Link unprocessable
cadl-20220331_pre.xml Edgar Link unprocessable
cadl-ex10_8.htm Edgar Link pending
cadl-ex31_1.htm Edgar Link pending
cadl-ex31_2.htm Edgar Link pending
cadl-ex32_1.htm Edgar Link pending
cadl-ex32_2.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R60.htm Edgar Link pending
R61.htm Edgar Link pending
R62.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending